Abedi AR. 2018 (1616 Abedi AR, Fallah-Karkan M, Allameh F, Ranjbar A, Shadmehr A. Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran. Res Rep Urol. 2018; 10:1-6.) |
Retrospective study |
Iran |
Shohada-e-Tajrish Hospital database (2006-2016) |
TURP:315 OP:108 (TURP:40, OP:44) |
NA |
68.74±9.87 |
80.56±25.12 |
21.47±13.44 |
NA |
TURP:12.6 OP:40.7 |
Andrèn O. 2009 (1717 Andrèn O, Garmo H, Mucci L, Andersson SO, Johansson JE, Fall K. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer. 2009; 100:170-3.) |
Cross-sectional study |
Sweden |
Swedish National Inpatient Register (1970-2003) |
TURP:72322 OP:4456 (23.288) |
NA |
NA |
NA |
NA |
NA |
OP:30.3 |
Argyropoulos A. 2005 (1818 Argyropoulos A, Doumas K, Farmakis A, Aristas O, Kontogeorgos G, Lykourinas M. Characteristics of patients with stage T1b incidental prostate cancer. Scand J Urol Nephrol. 2005; 39:289-93.) |
Retrospective study |
Greece |
Athens General Hospital (1999-2003) |
TURP:786 (34) |
T1a:17 T1b:17 |
69.7 |
NA |
5.1 |
NA |
TURP:4.3 |
Capogrosso P. 2018 (1919 Capogrosso P, Capitanio U, Vertosick EA, Ventimiglia E, Chierigo F, Oreggia D, at al. Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. Urology. 2018; 122:152-7.) |
Retrospective study |
Italy |
European academic center (2007-2016) |
OP:139 TURP:498 HoLEP:540 (74) |
T1a:64 T1b:10 |
66 |
76 |
3.2 |
PV, age and PSA |
OP:6.4 |
Elkoushy MA. 2015 (2020 Elkoushy MA, Elshal AM, Elhilali MM. Incidental Prostate Cancer Diagnosis During Holmium Laser Enucleation: Assessment of Predictors, Survival, and Disease Progression. Urology. 2015; 86:552-7.) |
Retrospective study |
Egypt |
HoLEP database (1998-2014) |
HoLEP:1242 (70) |
T1a:54 T1b:16 |
75.8±8.7 |
NA |
NA |
Age and PSA |
HoLEP:5.64 |
Froehner M. 2009 (2121 Froehner M, Buck LM, Koch R, Hakenberg OW, Wirth MP. Derivatives of prostate-specific antigen as predictors of incidental prostate cancer. BJU Int. 2009; 104:25-8.) |
Retrospective study |
Germany |
NA (1997-2006) |
TURP:693 (70) |
T1a:52 T1b:18 |
NA |
NA |
NA |
NA |
TURP: 10.1 |
Gunda D. 2018 (2222 Gunda D, Kido I, Kilonzo S, Nkandala I, Igenge J, Mpondo B. Prevalence and Associated Factors of Incidentally Diagnosed Prostatic Carcinoma among Patients Who Had Transurethral Prostatectomy in Tanzania: A Retrospective Study. Ethiop J Health Sci. 2018; 28:11-8.) |
Retrospective study |
Tanzaia |
Bugando University Hspital in Tanzania (2015) |
TURP:152 (33) |
T1a:11 T1b:22 |
69±9.4 |
92.7 |
8.5 |
PV, age and PSA |
TURP:21.71 |
Herlemann A. 2017 (2323 Herlemann A, Wegner K, Roosen A, Buchner A, Weinhold P, Bachmann A, et al. “Finding the needle in a haystack”: oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). World J Urol. 2017; 35:1777-82.) |
Retrospective study |
Germany |
Department of Urology of the Ludwig-Maximilians-University of Munich (2013-2014) |
TURP:229 HoLEP:289 (TURP:39, HoLEP:43) |
T1a:14 T1b:68 |
71 |
80 |
5.5 |
Age and PSA |
TURP:17 HoLEP:15 |
Kim M. 2014 (2424 Kim M, Song SH, Ku JH, Oh SJ, Paick JS. Prostate cancer detected after Holmium laser enucleation of prostate (HoLEP): significance of transrectal ultrasonography. Int Urol Nephrol. 2014; 46:2079-85.) |
Retrospective study |
Korea |
Seoul National University College of Medicine (2008-2011) |
HoLEP:458 (27) |
NA |
68.4±6.6 |
NA |
3.38±4.16 |
Age and PSA |
HoLEP:5.9 |
Matanhelia DM. 2019 (2525 Matanhelia DM, Croghan S, Nason GJ, O’Connell C, Galvin DJ. The Management of Incidental Prostate Cancer Following TURP. Ir Med J. 2019; 112:866.) |
Retrospective study |
Ireland |
Mater Misericordiae University Hospital (2007-2016) |
TURP:826 (72) |
T1a:37 T1b:35 |
73.3 |
44.2 |
5.25 |
NA |
TURP:8.7 |
Misraï V. 2019 (2626 Misraï V, Kerever S, Pasquie M, Bordier B, Guillotreau J, Palasse J, et al. Does mechanical morcellation of large glands compromise incidental prostate cancer detection on specimen analysis? A pathological comparison with open simple prostatectomy. World J Urol. 2019; 37:1315-20.) |
Retrospective study |
France |
Rennes Hospital (2013-2018) |
OP:393 HoLEP:345 (OP:33, HoLEP:34) |
T1a:28 T1b:39 |
69 |
110 |
6.6 |
NA |
OP:8.5 HoLEP:9.9 |
Nunez R. 2011 (2727 Nunez R, Hurd KJ, Noble BN, Castle EP, Andrews PE, Humphreys MR. Incidental prostate cancer revisited: early outcomes after holmium laser enucleation of the prostate. Int J Urol. 2011; 18:543-7.) |
Retrospective study |
America |
Department of Urology of Mayo Clinic (2007-2010) |
HoLEP:240 (28) |
T1a:14 T1b:14 |
73 |
71.2 |
3.3 |
NA |
HoLEP:11.7 |
Ohwaki K. 2017 (2828 Ohwaki K, Endo F, Shimbo M, Fujisaki A, Hattori K. Comorbidities as predictors of incidental prostate cancer after Holmium laser enucleation of the prostate: diabetes and high-risk cancer. Aging Male. 2017; 20:257-60.) |
Retrospective study |
Japan |
St. Luke's International Hospital (2008-2014) |
HoLEP:654 (41) |
NA |
70 |
66 |
6.1 |
PV and PSA |
HoLEP:6.3 |
Otsubo S. 2015 (2929 Otsubo S, Yokomizo A, Mochida O, Shiota M, Tatsugami K, Inokuchi J, et al. Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate. World J Urol. 2015; 33:329-33.) |
Retrospective study |
Japan |
Southwest Urological Clinic of Japan (2006-2011) |
HoLEP:365 (25) |
NA |
68 |
55.5 |
4.5 |
NA |
HoLEP:6.8 |
Otto B. 2014 (3030 Otto B, Barbieri C, Lee R, Te AE, Kaplan SA, Robinson B, et al. Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. Adv Urol. 2014; 2014:627290.) |
Retrospective study |
America |
New York-Presbyterian Hospital (2006-2011) |
TURP:760 (11) |
T1a:9 T1b:2 |
71 |
92.4 |
NA |
NA |
TURP:1.4 |
Perera M. 2016 (3131 Perera M, Lawrentschuk N, Perera N, Bolton D, Clouston D. Incidental prostate cancer in transurethral resection of prostate specimens in men aged up to 65 years. Prostate Int. 2016; 4:11-4.) |
Prospective study |
Australia |
Ludwig Institute for Cancer Research, Austin Hospital (2010-2013) |
TURP:923 (243) |
T1a:109 T1b:134 |
NA |
65 |
NA |
NA |
TURP:26.3 |
Pirša M. 2018 (3232 Pirša M, Pezelj I, Knežević M, Spajić B, Tomašković I, Reljić A, et al. Incidental Prostate Cancer in Patients Treated for Benign Prostate Hyperplasia in the Period of 21 Years. Acta Clin Croat. 2018; 57 (Suppl 1):71-6.) |
Retrospective study |
Croatia |
Department of Urology in Sestre milosrdnice University Hospital Center (1997-2017) |
TURP:4.372 (265) |
T1a:119 T1b:146 |
74.5 |
56 |
NA |
NA |
TURP:6.1 |
Porcaro AB. 2021 (3333 Porcaro AB, Siracusano S, Amigoni N, Tafuri A, Rizzetto R, Shakir A, et al. The Influence of Endogenous Testosterone on Incidental Prostate Cancer after Transurethral Prostate Resection. Urol Int. 2021; 105 (9-10):826-34.) |
Retrospective study |
Italy |
Department of Urology of University of Verona (2017-2019) |
TURP:389 (18) |
T1a:11 T1b:7 |
70 |
55 |
2.9 |
NA |
TURP:4.6 |
Rosenhammer B. 2018 (3434 Rosenhammer B, Lausenmeyer EM, Mayr R, Burger M, Eichelberg C. HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis. World J Urol. 2018; 36:2035-41.) |
Retrospective study |
Germany |
University of Regensburg (2016-2017) |
TURP:60 HoLEP:60 (TURP:5, HoLEP:14) |
T1a:12 T1b:7 |
71.5±7.9 |
74.2±13.9 |
4.99±3.12 |
PV, age and PSA |
TURP:8.3 HoLEP:23.3 |
Sakamoto H. 2014 (3535 Sakamoto H, Matsumoto K, Hayakawa N, Maeda T, Sato A, Ninomiya A, et al. Preoperative parameters to predict incidental (T1a and T1b) prostate cancer. Can Urol Assoc J. 2014; 8:E815-20.) |
Retrospective study |
Japan |
Tokyo Saiseikai Central Hospital (2006-2011) |
TURP:307 (31) |
T1a:18 T1b:13 |
69.2 |
61 |
5.4 |
PV, age and PSA |
TURP:10.1 |
Skrzypczyk MA. 2014 (3636 Skrzypczyk MA, Dobruch J, Nyk L, Szostek P, Szempliński S, Borówka A. Should all specimens taken during surgical treatment of patients with benign prostatic hyperplasia be assessed by a pathologist? Cent European J Urol. 2014; 67:227-32.) |
Retrospective study |
Poland |
Centre of Postgraduate Medical Education in Warsaw (2004-2010) |
OP:145 TURP:823 (34) |
T1a:19 T1b:15 |
71 |
70 |
3.36 |
PSA |
OP:3.5 |
Tonyali S. 2021 (3737 Tonyali S, Ceylan C, Aglamis E, Dogan S, Tastemur S, Karaaslan M. Is there a PSA cut-off value indicating incidental prostate cancer in patients undergoing surgery for benign prostatic hyperplasia? Arch Ital Urol Androl. 2021; 93:31-4.) |
Retrospective study |
Turkey |
Turkiye Yuksek Ihtisas Training and Research Hospital (2008-2018) |
OP:36 TURP:281 (21) |
T1a:10 T1b:11 |
69 |
NA |
3.24 |
NA |
OP:6.6 |
Yoo C. 2012 (88 Yoo C, Oh CY, Kim SJ, Kim SI, Kim YS, Park JY, et al. Preoperative clinical factors for diagnosis of incidental prostate cancer in the era of tissue-ablative surgery for benign prostatic hyperplasia: a korean multi-center review. Korean J Urol. 2012; 53:391-5.) |
Retrospective study |
Korea |
Yonsei University College of Medicine (2004-2008) |
TURP:1.613 (78) |
T1a:32 T1b:46 |
71.1±7.6 |
59.5±30.5 |
4.7±4.2 |
PV, age and PSA |
TURP:6.6 |